# NCT04628767 (NCT04628767)

> Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04628767
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Renal Pelvis and Ureter Urothelial Carcinoma
- Interventions: Biopsy Procedure; Biospecimen Collection; Cisplatin; Computed Tomography; Doxorubicin Hydrochloride; Durvalumab; Gemcitabine Hydrochloride; Magnetic Resonance Imaging; Methotrexate; Pegfilgrastim; Therapeutic Conventional Surgery; Vinblastine Sulfate
- Enrollment: 131
- Primary outcome: Event-free survival (EFS) (Cisplatin eligible cohort: Arms A and B)
- Primary outcome: Pathologic complete response (pCR) (Cisplatin ineligible cohort: Arm C)

## Indexed commentary on NCT04628767 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct04628767
